Byam Rebecca 4
4 · HCW Biologics Inc. · Filed Oct 23, 2023
Insider Transaction Report
Form 4
Byam Rebecca
Chief Financial Officer
Transactions
- Exercise/Conversion
Common Stock
2023-10-19$0.14/sh+47,249$6,615→ 621,195 total - Exercise/Conversion
Stock Option Grant (Right to Buy)
2023-10-19−47,249→ 0 totalExercise: $0.14Exp: 2029-12-19→ Common Stock (47,249 underlying)
Footnotes (1)
- [F1]These option shares were part of a stock option grant covering 135,000 shares of common stock. 20% of the total shares subject to the stock option grant vested on October 10, 2020; 20% of the total shares subject to the stock option grant vested on October 10, 2021; 25% of the total shares subject to the stock option grant vested on October 10, 2022; and 35% of the total shares subject to the stock option grant vested on October 10, 2023, subject to her continuous service through the applicable vesting date. The option is subject to additional vesting acceleration pursuant to her Employment Agreement.